


**From:** "whistleblower"  
**Sent:** Fri, 8 Aug 2025 09:30:31 +0000  
**To:** [REDACTED]  
**Subject:** RE: URGENT: Regulatory Breach – Unlicensed Supply of POMS to Northern Ireland Windsor agreement. MHRA failure to act (3+ weeks since first notified)

Do you have the previous inspection report?

Does that identify any additional sites being used by the company.

In the meantime, we could look at other ways of obtaining the same intelligence and parallel sourcing it, which would not put the source at risk. What other agencies have passed this information to GDP? We could potentially use their information and intelligence and act on that



Intelligence Unit  
Criminal Enforcement Unit  
Medicines & Healthcare products Regulatory Agency (MHRA)  
NIBSC, Blanche Lane, South Mimms, EN6 3QG

---

**From:** [REDACTED]  
**Sent:** 08 August 2025 10:20  
**To:** whistleblower <whistleblower@mhra.gov.uk>  
**Subject:** RE: URGENT: Regulatory Breach – Unlicensed Supply of POMS to Northern Ireland Windsor agreement. MHRA failure to act (3+ weeks since first notified)

Ok, thanks [REDACTED]. I will take this back to management. We will have to balance this against the risk of serious patient harm, given the high impact of the medicine in recovering from overdoses. I will let you know what conclusion we come to



---

**From:** whistleblower <[whistleblower@mhra.gov.uk](mailto:whistleblower@mhra.gov.uk)>  
**Sent:** 08 August 2025 10:17  
**To:** [REDACTED]  
**Subject:** RE: URGENT: Regulatory Breach – Unlicensed Supply of POMS to Northern Ireland Windsor agreement. MHRA failure to act (3+ weeks since first notified)

Its not a case of its credibility – it's more of a case of the risk to the surce – he has basically told every man and his dog that he is a WB. So we have to tread very carefully should we act on it – especially as it is so specific



Intelligence Unit  
Criminal Enforcement Unit  
Medicines & Healthcare products Regulatory Agency (MHRA)  
NIBSC, Blanche Lane, South Mimms, EN6 3QG

---

**From:** [Redacted]  
**Sent:** 07 August 2025 22:34  
**To:** whistleblower <[whistleblower@mhra.gov.uk](mailto:whistleblower@mhra.gov.uk)>  
**Subject:** RE: URGENT: Regulatory Breach – Unlicensed Supply of POMS to Northern Ireland Windsor agreement. MHRA failure to act (3+ weeks since first notified)

H [Redacted]

Thanks for this. I suppose I need to understand if there is any credibility you can ascertain for the unlicensed premises query? If the company is actually acting in the way as described and the quality of the naloxone is compromised we would need to take that very seriously and make some difficult positions.

If your assessment is that the credibility is low however I would be more comfortable.

Best,



---

**From:** whistleblower <[whistleblower@mhra.gov.uk](mailto:whistleblower@mhra.gov.uk)>  
**Sent:** 07 August 2025 13:23  
**To:** [Redacted]  
**Subject:** RE: URGENT: Regulatory Breach – Unlicensed Supply of POMS to Northern Ireland Windsor agreement. MHRA failure to act (3+ weeks since first notified)

Hi [Redacted]

I won't go into details, however there will be no intelligence reports disseminated based on the information provided due to the self-disclosures made and non-adherence to instructions. The risk is too high to proceed from our perspective.

I anticipate further interactions with the referrer, however, I advise that no action is taken from information supplied directly from this referrer

Cheers



Senior Criminal Enforcement Officer  
Intelligence Unit  
Criminal Enforcement Unit  
Medicines & Healthcare products Regulatory Agency (MHRA)  
NIBSC, Blanche Lane, South Mimms, EN6 3QG

---

**From:** [Redacted]  
**Sent:** 07 August 2025 13:00  
**To:** whistleblower <[whistleblower@mhra.gov.uk](mailto:whistleblower@mhra.gov.uk)>  
**Subject:** FW: URGENT: Regulatory Breach – Unlicensed Supply of POMS to Northern Ireland Windsor agreement. MHRA failure to act (3+ weeks since first notified)

Hi [Redacted]

The WB seems to be very vocally spreading this message to as many bodies as they can. I have asked [Redacted] to mark this as "MHRA aware" if they receive any further queries.

The sterilisation aspect here is clearly breached. I will delete the message chain, but can we confirm if the WB has been responded to yet? If they are happy to waive the WB aspect, I can discuss with them directly, but will be directed by your judgement.

Best,



---

**From:** [Redacted]  
**Sent:** 07 August 2025 11:53  
**To:** [Redacted]  
**Subject:** FW: URGENT: Regulatory Breach – Unlicensed Supply of POMS to Northern Ireland Windsor agreement. MHRA failure to act (3+ weeks since first notified)

Hi [Redacted]

I hope that you are keeping well.

I have received the below correspondence from one of our Trusts and have since been advised that other Trusts have also received the same. It appears that the matter has been referred to MHRA in one of the attachments. Are you aware of the concern? I feel the Trusts are just seeking some reassurance that they will be advised of any required actions.

Happy to discuss.

Kind regards,

[Redacted]

Department of Health  
D 4.6 Castle Buildings  
Stormont Estate  
Belfast  
BT4 3SQ

[Redacted]

---

**From:** [Redacted]

**Sent:** 07 August 2025 10:50

**To:** [Redacted]

**Cc:** [Redacted]

**Subject:** FW: URGENT: Regulatory Breach – Unlicensed Supply of POMS to Northern Ireland Windsor agreement. MHRA failure to act (3+ weeks since first notified)

Hello [Redacted]

Please see email trail below and attachments. Can you advise on whether we need to look at this regionally or whether the MHRA need to address nationally?

It seems to have been emailed initially to Northern Trust ([Redacted] was not aware of it) and it came to me via WHSCT complaints team – so possibly other Trusts Bcc'ed the email.

Regards

[Redacted]

Regards

[Redacted]

Mobile: [REDACTED]

---

**From:** [REDACTED]  
**Sent:** 06 August 2025 17:46  
**To:** [REDACTED]  
**Cc:** [REDACTED]  
**Subject:** FW: URGENT: Regulatory Breach – Unlicensed Supply of POMS to Northern Ireland Windsor agreement. MHRA failure to act (3+ weeks since first notified)

Hi [REDACTED]

Please see below from [REDACTED] regarding correspondence we have received in the Complaints email account (below and attached).

I do not feel this is something we can take through the complaints process, however, welcome your thoughts regarding any necessary action – how to respond back to [REDACTED]?

Not sure if you are aware of this issue previously?

Many thanks

---

**From:** Complaints Department <[Complaints.Department@westerntrust.hscni.net](mailto:Complaints.Department@westerntrust.hscni.net)>  
**Sent:** 06 August 2025 17:10  
**To:** [REDACTED]  
**Subject:** FW: URGENT: Regulatory Breach – Unlicensed Supply of POMS to Northern Ireland Windsor agreement. MHRA failure to act (3+ weeks since first notified)

Hi [REDACTED]

Sharing with you to see your thoughts. This has been sent to NHSCT and we must be Bcc's into. Is this something we take forward as a complaint or pass to Pharmacy?

I have not acknowledged.

Thanks

---

**From:** [REDACTED]  
**Sent:** 01 August 2025 13:59  
**To:** Raising Concerns (NHSCT) <[Raising.Concerns@northerntrust.hscni.net](mailto:Raising.Concerns@northerntrust.hscni.net)>  
**Subject:** URGENT: Regulatory Breach – Unlicensed Supply of POMS to Northern Ireland Windsor agreement. MHRA failure to act (3+ weeks since first notified)

You don't often get email from [REDACTED] [Learn why this is important](#)

**CAUTION - EXTERNAL EMAIL**

**Do not click on links or attachments that are not expected**

**Never trust - always verify**

**Stay Alert - Think before you Click - Stop a potential Cyber Attack**

**\*\*Warning\*\*** This email contains suspicious content. Please take care to proceed.

Dear Team,

I am writing to raise a serious and time-sensitive concern regarding the distribution of prescription-only medicines – including naloxone and water for injection – into Northern Ireland by Exchange Supplies Ltd, under contract to HSCNI.

These medicines were stored and dispatched from an unlicensed premises (Romans Building, Dorchester DT1 1ST) in direct breach of the Medicines Act 1968 and GDP guidelines.

As a former [REDACTED] (WDA Licence), I was professionally involved with the company and have attached a full protected disclosure outlining:

- Documented evidence of cross-border medicine movements
- Deliberate deception of MHRA inspectors
- Regulatory inaction following my internal and external alerts
- Retaliatory legal threats following disclosure attempts

This issue presents an immediate risk to public health, especially given the temperature sensitivity of naloxone, the vulnerable populations it serves, and the volume of compromised stock involved.

**For the avoidance of doubt:** naloxone is temperature-sensitive and degrades with heat. Any cases in the last two years where multiple doses were required may stem directly from illegal storage, dispatch from unlicensed premises, and courier-based distribution in breach of regulatory controls.

You will find three attachments:

1. Full Disclosure Report – includes primary source material and analysis
2. Supporting Screenshots – confirming the systemic breaches
3. Contextual Addendum – clarifying my role and withdrawal from the organisation

These documents are available for independent verification and have already been submitted to relevant regulatory bodies. However, I believe HSCNI deserves to review this directly, given the implications for your contracted service provision and reputational accountability.

Please confirm receipt and let me know who will be reviewing this.

I am available for questions or clarification at any stage and will treat any engagement in confidence.

My primary concern is the safety of vulnerable populations (specifically people who inject drugs). My secondary concern is ensuring accountability for those involved in what I believe to be an ongoing criminal conspiracy. Kind regards,

 Exchange Supplies Ltd

The information contained in this email and any attachments is confidential and intended solely for the attention and use of the named addressee(s). No confidentiality or privilege is waived or lost by any mistransmission. If you are not the intended recipient of this email, please inform the sender by return email and destroy all copies. Any views or opinions presented are solely those of the author and do not necessarily represent the views of HSC. The content of emails sent and received via the HSC network may be monitored for the purposes of ensuring compliance with HSC policies and procedures. Please be aware that e-mail may not be a secure medium. This e-mail (whether you are the sender or the recipient) may be monitored and monitoring and blocking software may be used. While HSC takes precautions in scanning outgoing emails for computer viruses, no responsibility will be accepted by HSC in the event that the email is infected by a computer virus. Recipients are therefore encouraged to take their own precautions in relation to virus scanning. All emails held by HSC may be subject to public disclosure under the Freedom of Information Act 2000. All emails held by HSC may also be disclosed, where required, under the UK GDPR and Data Protection Act 2018.

DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click

[DHTermsAndConditions](#)

DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click

[DHTermsAndConditions](#)

DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the

Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click [DHTermsAndConditions](#)

DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click [DHTermsAndConditions](#)

DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click [DHTermsAndConditions](#)